Alligator CEO Discusses Pipeline Additions, Milestone Expectations And The IO Deal Landscape
Alligator Bioscience’s Per Norlen discusses the latest addition to its pipeline, a first-in-class bispecific tumor-localized antibody targeting the checkpoint inhibitor CTLA-4.
You may also be interested in...
Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.
Following a deal, worth potentially $700m plus, signed in 2015 with Johnson & Johnson’s Janssen Biotech, Swedish biotech Alligator Biosciences AB is well placed to drive its clinical pipeline. During the Biotech Showcase, CEO Per Norlén outlined to Scrip the current status of the pipeline and its plans moving forward, which include having five clinical programs in place by the end of 2019.
Johnson & Johnson's Janssen Biotech, Inc. has snapped up Alligator Bioscience's immuno-oncology MAb, ADC-1013, in a deal potentially worth $700m to the small Swedish drug developer.